Available Technologies

  1. Hybridoma: Leading scientist has extensive experience, previously worked for Novartis Shanghai and Wuxi Biologics, Shanghai. Successfully developed x therapeutic antibody candidates covers wide variety of diseases and targets include (membrane protein, serum protein, etc), familiar with various kinds of techniques involved in DNA immunization.

  2. Phage Display: Leading scientists have extensive experience in phage ScFv library construction, phage panning and characterization. Unique experience on panning internalization antibody with living target cells.

  3. Computer Aided Design: Schordinger Bioluminate and Maestro. Ab Studio has humanized and optimized more than 20 antibodies from Mar 2017 to Oct 2017.

Patented Unique Technologies

Imbalanced Bispecific Antibody Technology Platform

What is an imbalanced bispecific antibody?

A “Knob-into-hole plus common LC” version allowing two arms to have very different binding affinity to each one’s own antigen.

Why “imbalanced”?

Imbalanced binding affinity is required for the follow three applications:

Bispecific involves a CD3 binder
Bispecific against a CSA (cancer specific antigen) and a CAA (cancer associated antigen)
Bispecific against one target for CNS and another target on BBB
How to make “imbalanced bispecific antibody”?

VL part:

  1. If VLa and VLb light chain homology >80%, design a VLc based on VLa via computer aided design: Maintain VHaVLc’s affinity as close as that of VHaVLa, allow VHbVLc to have reduced affinity compared to VHbVLb.

  2. If VLa and VLb light chain homology < 80%, construct phage ScFV library: VHs of the ScFV library are human germline VH library VLs of the ScFV library are VLa and its mutants derived from error prone PCR at less than 20% of mutation frequency.

VH part:

Use computer aided design to separate the biochemical and biophysical features of VHa and VHb in order to isolate AB from AA and BB at a higher efficiency.

Strategy for Developing Internalization Antibody

Unique feature of second strategy: Screening internalization caused by primary Ab.

Our method avoids internalization triggered by secondary antibody binding